Company profile
Regeneron Pharmaceuticals
Profiled by the AIDE Institute
Regeneron Pharmaceuticals (REGN) has an AIDE Index 2.0 (Sector) score of 41.74 out of 100, placing it #45 of 59 companies in the Health Care sector. Its Matrix Quadrant (Sector) is Health Care Emerging Adopters. The AIDE Index measures observable AI adoption through public evidence, scored against sector peers.
- Edition
- AIDE Index 2.0 · S&P 500 Round 2, 2026-Q3 · Current edition
- Matrix Quadrant (Sector)
- Emerging Adopter
- Health Care sector position
- #45
- of 59 Health Care peers
- AIDE Index 2.0 (Sector)
- AIDE Index 2.0 (Sector): 41.74 / 100
Where does Regeneron Pharmaceuticals sit among Health Care peers?
Matrix Quadrant (Sector), AIDE Index 2.0: Health Care Emerging Adopters
Horizontal axis: Strategic Intent. Vertical axis: Operational Integration. Each divider is the median of the same GICS sector in the same edition.
Stealth Adopters
Lower Strategic Intent, higher Operational Integration
AI Trailblazers
Higher Strategic Intent, higher Operational Integration
Emerging Adopters
Lower Strategic Intent, lower Operational Integration
This company’s category
AI Visionaries
Higher Strategic Intent, lower Operational Integration
Quadrants are assigned against the median of the same GICS sector in the same edition. Exact axis values and positions within a quadrant are not public.
- Ticker
- REGN
- GICS sector
- Health Care
- Industry
- Biotechnology
Step 1
Compare with a competitor
Step 2
Share your score
Step 3
Want more?
License AIDE data for the full peer set, pillar evidence and documented use cases.
Request the full analysis
Official company websiteregeneron.com
Side by side · Health Care · AIDE Index 2.0, current edition
Compare companies
| Public evidence snapshot | ||||
|---|---|---|---|---|
| AIDE Index 2.0 (Sector) | 41.74 / 100+49.8% | Competitor information locked | Competitor information locked | Competitor information locked |
| Sector rank | #45 of 596 positions | Competitor information locked | Competitor information locked | Competitor information locked |
| Matrix Quadrant (Sector) | Health Care Emerging Adopters | Competitor information locked | Competitor information locked | Competitor information locked |
| Literacy (Sector) | 34.94+208.1% | Competitor information locked | Competitor information locked | Competitor information locked |
| Advocacy (Sector) | 27.00+27.1% | Competitor information locked | Competitor information locked | Competitor information locked |
| Orientation (Sector) | 58.33+8.3% | Competitor information locked | Competitor information locked | Competitor information locked |
| Implementation (Sector) | 46.67+86.6% | Competitor information locked | Competitor information locked | Competitor information locked |
| Industry | Biotechnology | Competitor information locked | Competitor information locked | Competitor information locked |
| Edition | AIDE Index 2.0 · S&P 500 Round 2, 2026-Q3 | Competitor information locked | Competitor information locked | Competitor information locked |
| Next step | Request the full analysis | Request the full analysis | Request the full analysis | Request the full analysis |
Enter your email to access competitor information
Competitor values stay hidden until you submit the Health Care sector form. Regeneron Pharmaceuticals stays visible.
AIDE Index (Sector) is relative to companies in the same GICS sector and the same edition. It is not a cross-sector ranking. All values are from AIDE Index 2.0 (S&P 500 Round 2, 2026-Q3). This is a sector-relative signal, not a full organizational benchmark.
Arrows compare the two published editions for each company. They show how published scores and ranks changed; they do not establish what caused the changes.
Documented from public evidence
How is Regeneron Pharmaceuticals using AI?
A small, selected preview of AI use by Regeneron Pharmaceuticals that the AIDE Institute has documented from public sources such as filings, earnings calls and company announcements. It is not the complete set.
Enter your email to access more information
AIDE Index 2.0 · S&P 500 Round 2, 2026-Q3 · Current edition
What does the AIDE Index show for Regeneron Pharmaceuticals?
This is a sector-relative signal for AIDE Index 2.0, not a full organizational benchmark.
Enter your email to access more information
Editions
How do the published editions compare for Regeneron Pharmaceuticals?
Enter your email to access more information
Quick answers about Regeneron Pharmaceuticals
What is Regeneron Pharmaceuticals’ AIDE Index 2.0 (Sector) score?
Regeneron Pharmaceuticals has an AIDE Index 2.0 (Sector) score of 41.74 out of 100. The score is sector-relative: it compares Regeneron Pharmaceuticals only with other Health Care companies.
Where does Regeneron Pharmaceuticals place in Health Care?
Regeneron Pharmaceuticals places #45 of 59 Health Care companies on AIDE Index 2.0 (Sector). #1 is the highest score in the sector.
What is Regeneron Pharmaceuticals’ Matrix Quadrant (Sector)?
Regeneron Pharmaceuticals’ Matrix Quadrant (Sector) is Health Care Emerging Adopters. The quadrant is assigned within the Health Care sector, not across all sectors.
What do the four pillars show?
Literacy reflects what leaders know, Advocacy what leaders say, Orientation what the organization prioritizes and Implementation what the organization builds. Each pillar (Sector) is scored from 0 to 100 against the same sector peer group. See the AIDE Index methodology.
About this profile
This public profile is a snapshot of the AIDE Index 2.0 (Sector) result for Regeneron Pharmaceuticals: its score and position among Health Care companies, its four pillars and its Matrix Quadrant (Sector), measured from public evidence rather than surveys. The use-case summaries are a small, selected preview of documented AI use.
It shows where Regeneron Pharmaceuticals stands within its sector on the public record. Deeper interpretation, sector context and the source-linked evidence behind each result are part of AIDE’s full analysis, available by request.
Definitions
- AIDE Index 2.0 (Sector)
- A 0 to 100 measure of observable AI adoption built from public evidence and scored against companies in the same GICS sector and edition. It does not establish financial returns or capture every internal AI initiative. See the AIDE Index methodology.
- Sector position
- Where the company places among Health Care companies on AIDE Index (Sector). #1 is the highest score in the sector.
- Matrix Quadrant (Sector)
- One of the four AI-Driven Enterprise Matrix quadrants, assigned within the sector. See how the AIDE Matrix works.
- Pillars (Sector)
- Literacy, Advocacy, Orientation and Implementation, each scored from 0 to 100 against the same sector peer group.
Full company analysis
What does the public evidence mean for Regeneron Pharmaceuticals?
Get the complete detected use-case portfolio, source-linked evidence, deployment context, competitor patterns and expert interpretation from AIDE’s enterprise AI research team.
AIDE’s research leadership includes Paul Cheek, CEO and Co-Founder of AIDE and Senior Lecturer at MIT Sloan, alongside researchers and practitioners with experience in AI, strategy and enterprise transformation.
More Health Care company profiles
Companies placed near Regeneron Pharmaceuticals on AIDE Index 2.0 (Sector).
Beyond the public profile
What does the public evidence mean for Regeneron Pharmaceuticals?
The public profile shows the approved signals. A full AIDE analysis examines the source record behind them and explains what the pattern means for Regeneron Pharmaceuticals in its Health Care context. The work is built from public, verifiable evidence by a specialist research team focused on enterprise AI adoption.
The analysis connects leadership, strategy, talent and deployed AI to the complete set of detected use cases, cited sources, deployment stages and reported outcomes. Company-reported claims remain clearly identified as claims.
The full analysis is designed to:
- Distinguish stated AI ambition from observable execution.
- Explain how the four AIDE pillars combine within the correct sector context.
- Review the complete set of detected use cases and the evidence attached to each one.
- Surface evidence gaps, contradictions and unanswered questions that deserve follow-up.
- Produce a cited briefing for strategy, diligence and board-level discussion.
AIDE’s research leadership includes Paul Cheek, CEO and Co-Founder of AIDE and Senior Lecturer at MIT Sloan, alongside researchers and practitioners with experience in AI, strategy and enterprise transformation.